Biotechnology | North America COVID-19: Increasing ConvictionMultiple Vaccine Candidates WillHave Pivotal Data Before YE20 While a pre-election result is possible, we see early-to-mid November as our base case for PhIII data. Pfizer/BioNTech and Moderna appear slightly ahead of AstraZeneca for US PhIII data, though we note many details on the PhIIIs have not been disclosed which could impact our projected…
Soooooo… feels like the market is running in place, right? Since hitting its initial 2023 high on February 2nd...
Equities are facing one of the best backdrops for sustained gains next year. After a prolonged period of elevated...
That was something for all the market pundits and critics to behold last week was it not? The mantra...
It’s enough to make you close up shop and seek out a new career if you’re a portfolio or...
Last week was a measured action against extremes. The downturn in U.S. equities last week ended a streak of...
“While so many worry about trying to grab a few pennies in front of a steamroller… We could be...
Welcome back to Finom Group’s weekly Research Report, as we kick-off our 3-week reporting cycle. Two weeks ago, during...
MarketWatch.com – Top Stories
